Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
House dust mite allergen extract (ALK-Abelló)
- Development stage
- Approved
- Lead developer
- ALK Abelló
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual, Subcutaneous
01
Overview
House dust mite allergen extract is a biologic drug used for the treatment of allergic rhinitis (with or without conjunctivitis) caused by sensitization to house dust mites. It contains a mixture of allergenic proteins derived from Dermatophagoides farinae and Dermatophagoides pteronyssinus (the most common household dust mites)[1][4][5]. The drug is available as sublingual tablets (Odactra in the US, Acarizax in Canada) and as standardized injectable extracts for diagnostic and therapeutic use[1][3][8]. Its mechanism involves exposing the immune system to controlled amounts of house dust mite allergens to induce immunological tolerance. This process increases IgG antibodies that compete with IgE antibodies responsible for allergic reactions and may also modulate T-cell responses[5]. The primary indication is allergic rhinitis due to house dust mites.
- Brand names
- OdactraAcarizax
- Other names
- house dust mite allergen extractstandardized mitemixed injection
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on House dust mite allergen extract (ALK-Abelló).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on House dust mite allergen extract (ALK-Abelló).